Dr Hans Hammers discusses highlights from the Thirteenth International Kidney Cancer Symposium

Dr Hans Hammers (Johns Hopkins, MD) discusses highlights from the Thirteenth International Kidney Cancer Symposium. Immunotherapies have received significant interest: immune checkpoint inhibitors have the potential to durably control disease. Although significant progress has been made in the clear cell renal cell carcinoma (RCC) subtype, research in therapies for non-clear cell RCC (nccRCC) has been relatively neglected.

Year of Production:
Running Time:
Color/Sound:

2014
02:17
Color/Sound

Comments are closed.